Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Industry to Biden: Count Us In On Cancer Moonshot

Executive Summary

AdvaMed says the medtech industry needs to at the table to advise the government on investments that could lead to future cancer diagnostics and treatments.

You may also be interested in...

FDA Draft Guidance Takes Aim At Racial, Ethnic Disparities In Clinical Trials

The US agency has outlined steps industry can take to ensure clinical trials include a broader representation of underrepresented racial and ethnic groups.

Biden Announces New Direction For COVID-19 Policy In Annual Address

Proposals in the speech that could affect the device industry include “one-stop shops” for COVID-19 testing and treatment, additional funding to stockpile tests and masks, and a new government center devoted to health care research.

Device-Makers Can Help With Cancer ‘Moonshot,' AdvaMed Tells Biden

Medical technology plays an important role in cancer treatment and cures via diagnostics and precision medicine, advanced imaging, radiation therapy and surgical oncology, AdvaMed told Vice President Joe Biden in a March 31 letter asking for a meeting with the National Cancer “Moonshot” Task Force.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts